Perspective Therapeutics (CATX) Tax Provisions (2022 - 2023)
Perspective Therapeutics' (CATX) quarterly Tax Provisions came in at $1.2 million in Q4 2023, up 213.08% year-over-year from $383932.1 in Q4 2022, and up 111.45% quarter-over-quarter from -$10.5 million in Q1 2023.
Powered by 
Analysis
Perspective Therapeutics (CATX) Tax Provisions (2022 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Tax Provisions across 2 years of filings, most recently posting $1.2 million for Q4 2023.
- In Q4 2023, Tax Provisions rose 213.08% year-over-year to $1.2 million; the TTM figure through Dec 2023 stood at -$9.3 million (down 774.69% YoY), while the FY2023 annual figure was -$9.3 million, changed N/A from the prior year.
- Tax Provisions came in at $1.2 million for Q4 2023 at Perspective Therapeutics, up from -$10.5 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $1.2 million in Q4 2023 to a low of -$10.5 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1.20 Mn |
| Mar 31, 2023 | -10.50 Mn |
| Dec 31, 2022 | -1.06 Mn |